Biopure Corporation (Biopure) develops oxygen therapeutics, which are intravenously administered to deliver oxygen to the body’s tissues. Its products are Oxyglobin, for veterinary use, and Hemopure, for human use. The Company, through distributors, sells Oxyglobin in the United States and Europe for the treatment of anemia in dogs. Biopure sells Hemopure in South Africa for use in adult surgery patients, who are acutely anemic and for eliminating, delaying, or reducing allogenic red blood cell transfusions in these patients. During the fiscal year ended October 31, 2008 (fiscal 2008), the Company shut down its manufacturing facility in Cambridge and its processing facility in Pennsylvania. In July 2009, the Company filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code in the United States Bankruptcy Court for the District of Massachusetts.